Prescriber Scope of Practice for Weight Loss/GLP-1 in Florida

If you’re a psychiatrist or PMHNP wondering whether you can legally prescribe GLP-1 agonists like Ozempic, semaglutide, or controlled weight-loss drugs like phentermine through telehealth — you’re not alone. The intersection of telehealth law, DEA controlled substance rules, and state-specific obesity treatment regulations is confusing, and the stakes are high. Get it wrong and you could face board complaints, DEA scrutiny, or worse.

Here’s what you actually need to know about prescribing weight-loss medications via telemedicine in 2025, state by state, with the real rules and business realities — not generic legal fluff.

The Bottom Line Up Front: DEA Rules and GLP-1s vs. Controlled Substances

First, the good news: GLP-1 agonists (semaglutide/Wegovy, tirzepatide/Mounjaro) are not controlled substances. You can prescribe them via telehealth in any state where you’re licensed, following that state’s standard telehealth prescribing rules. No DEA in-person exam required federally, no special registration needed beyond your normal medical license and prescriptive authority.

The complication: Older weight-loss medications like phentermine (Adipex-P) are Schedule IV controlled substances. Under the Ryan Haight Act, controlled substances normally require an in-person medical evaluation before a provider can prescribe via telemedicine. However, as of January 2026, the DEA extended COVID-era flexibilities through December 31, 2026, meaning you can still prescribe controlled substances via telehealth to new patients without an initial in-person visit — federally.

But here’s the catch: state law can be stricter than federal law. Some states like New York currently require an in-person exam before prescribing any controlled substance via telehealth (with narrow exceptions). Others like Florida and Texas allow it under certain conditions. And these rules are in flux — permanent DEA regulations are coming that will likely reimpose some in-person requirements or mandate special telemedicine registrations for controlled substances.

Bottom line for 2026: You can prescribe GLP-1s for weight loss via telehealth almost everywhere (check your state’s general telehealth exam requirements). For phentermine or other controlled weight-loss drugs, it depends on your state — and this window may close after 2026.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrists vs. PMHNPs: Scope of Practice Reality Check

Psychiatrists (MD/DO)

You have broad prescribing authority. Legally, nothing stops you from prescribing weight-loss medications — you’re a fully licensed physician. However, regulatory boards hold you to the same standard of care as any physician treating obesity. That means:

• Documenting appropriate patient selection (BMI ≥30, or ≥27 with comorbidities for FDA-approved obesity drugs)
• Obtaining informed consent about risks and benefits
• Following up regularly (some states like Florida mandate every 3 months minimum)
• Coordinating with the patient’s primary care provider when appropriate
• Incorporating lifestyle modification counseling, not just pills

The practical question: Are you competent to manage obesity treatment, or are you practicing outside your expertise? If you’re prescribing a GLP-1 to offset antipsychotic-induced weight gain in your existing psych patients — that’s well within your scope and defensible. If you’re launching a standalone weight-loss telehealth clinic with no obesity medicine training — you’re taking on liability risk. Some psychiatrists pursue American Board of Obesity Medicine (ABOM) certification to bolster credibility in this area.

Psychiatric Nurse Practitioners (PMHNPs)

This gets trickier. Your scope of practice is defined by your training and certification in psychiatric-mental health. Prescribing purely for obesity treatment may be viewed by state nursing boards as outside your scope, especially if you’re doing it independently without physician collaboration.

Reality:

• In states like Texas and Florida, nurse practitioners must practice within their education and training. A PMHNP treating obesity without a supervising physician (and ideally one with bariatric expertise) could face scrutiny.
• States with full practice authority for NPs (like California’s AB 890 pathway or Illinois’s FPA) don’t automatically solve this — you still need to practice within your competence. An experienced Family NP has more justification for managing weight loss than a psych NP, even if both have independent practice rights.
• Best practice: If you’re a PMHNP interested in this market, establish a collaborative relationship with an internist, family medicine doc, or obesity specialist who can provide oversight and handle medical complications.

Some PMHNPs have successfully integrated weight management into their practices by positioning it as part of holistic mental health care (addressing medication side effects, eating disorders, etc.) and collaborating appropriately. But launching a pure weight-loss clinic as a solo PMHNP is legally and professionally risky in most states.

State-Specific Rules That Actually Matter

Florida: The Compliance Gauntlet

Florida is one of the most regulated states for weight-loss prescribing, but it’s also telehealth-friendly if you follow the rules.

What’s allowed:

• Telehealth evaluations are explicitly permitted for weight loss treatment (as of the 2022 rule update)
• You can prescribe phentermine (Schedule IV) via telehealth — Florida’s ban on Schedule II teleprescribing doesn’t apply to Schedule III-V drugs
• Psychiatrists can prescribe Schedule II stimulants for psychiatric conditions via telehealth (the law carves out an exception for mental health treatment)

What you must do:

• Document patient’s BMI ≥30 (or ≥27 with comorbidities) or body fat percentage meeting thresholds
• Obtain written informed consent outlining risks of weight-loss medications
• Re-evaluate patients at least every 3 months via telehealth or in-person
• Provide each patient with Florida’s ‘Weight-Loss Consumer Bill of Rights’ (yes, this is legally required)
• Check the E-FORCSE PDMP before prescribing any controlled substance

Local reality: Florida has aggressive enforcement against ‘pill mills’ following the opioid crisis. Weight-loss clinics that don’t follow these protocols get flagged. The upside? Florida’s large, health-conscious population and snowbird demographics create strong demand for telehealth weight management.

PMHNP consideration: You’ll need a supervising physician agreement in Florida unless you qualify for autonomous practice (currently limited to certain specialties, not including psych NPs as of 2025).

New York: The In-Person Problem

New York reinstated strict controlled substance prescribing rules in 2025.

The rule: You cannot prescribe a controlled substance via telehealth to a new patient unless:

1. Another NY-licensed provider examined the patient in person within the last 12 months and shared records with you, OR
2. You’re covering for a colleague who saw the patient in person, OR
3. It’s an emergency with an existing patient (maximum 5-day supply)

What this means:

• You cannot start a new patient on phentermine via pure telehealth in New York
• You can prescribe GLP-1 agonists (not controlled) via telehealth without in-person visits
• You must check the NY PMP within 24 hours before prescribing any Schedule II-IV controlled substance

Workaround: Some telehealth providers partner with local clinics to handle the initial in-person visit, then continue care remotely. Others focus exclusively on non-controlled medications like GLP-1s and avoid the phentermine market entirely in NY.

PMHNP consideration: After 3,600 practice hours, NY NPs can practice independently — but treating obesity as a psych NP may still raise scope questions. Coordinate with a primary care colleague.

California: Flexibility with CPOM Constraints

California is generally telehealth-friendly but has unique corporate practice of medicine (CPOM) rules.

What’s allowed:

• Telehealth exam satisfies the ‘appropriate prior examination’ requirement for prescribing — no in-person needed if the standard of care is met
• No state ban on controlled substance teleprescribing (federal rules apply)
• NPs can eventually practice independently under AB 890 (2026 Phase 2), but only in their certified population focus

What you must do:

• Obtain and document telehealth consent from patients
• Query CURES PDMP before first controlled substance prescription and every 4 months thereafter
• Use e-prescribing for all medications

The CPOM trap: Only physicians can own medical practices in California. If you’re working with a telehealth platform or starting a weight-loss service, the business structure must comply with CPOM — typically a physician-owned professional corporation or a management services organization (MSO) arrangement. Non-physician owned ‘wellness clinics’ prescribing medications get shut down by the Medical Board.

2026 update: Medi-Cal (California’s Medicaid) will stop covering GLP-1 medications for weight loss in January 2026, positioning them as ‘non-covered.’ This will shift the market toward cash-pay models and telehealth services targeting privately insured or self-pay patients.

Texas: Delegation and Documentation

What’s allowed:

• Telehealth with live video establishes a valid patient relationship (no in-person requirement)
• Phentermine can be prescribed via telehealth under current federal extension
• Psychiatrists have full authority; NPs/PAs need prescriptive authority agreements

What you must do:

• Use synchronous audio-video for controlled substance prescriptions
• Check Texas PMP for controlled substances (required for opioids/benzos; best practice for all)
• Send treatment summary to patient’s primary care provider within 72 hours (with patient consent)

NP/PA reality: Texas requires very specific prescriptive authority delegation agreements. NPs and PAs cannot prescribe controlled substances independently — the delegating physician must review charts and be available for consultation per state admin code.

Market opportunity: Texas has one of the highest obesity rates in the U.S. Rural areas have limited access to specialists, creating telehealth demand. But regulators watch for improper delegation and advertising violations.

Pennsylvania & Illinois: Middle Ground

Both states allow telehealth prescribing without special in-person requirements, following federal DEA rules.

Pennsylvania:

• No specific state telehealth statute; relies on board guidance and standard of care
• Must check PA PDMP before prescribing opioids or benzos (each time), recommended for all controlled substances
• NPs need collaborative agreements; no independent practice yet

Illinois:

• Explicitly telehealth-friendly; allows relationship establishment via telemedicine
• Full Practice Authority available for experienced NPs (4,000+ hours)
• PDMP checks required for Schedule II narcotics

Both states are relatively low-regulation environments for telehealth, but you still need appropriate documentation and standard-of-care compliance.

The Economics: Why Telehealth Platforms Beat DIY Marketing

Here’s what no one tells you about starting a weight-loss practice: patient acquisition is expensive and time-consuming.

DIY marketing reality:

• SEO takes 6-12 months of consistent investment before generating meaningful patient flow
• Google Ads for ‘weight loss doctor’ or ‘GLP-1 prescription’ cost $15-40+ per click, and most clicks don’t convert
• Realistic cost per booked patient through PPC: $200-400+
• Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you compete with hundreds of providers
• Total all-in cost when you factor in agency fees, ad spend, staff time to qualify leads, and no-shows: easily $3,000-5,000/month with uncertain ROI

Platform model (like Klarity Health):

• Pay-per-appointment instead of upfront marketing spend
• Pre-qualified patients already matched to your availability and specialty
• No wasted ad spend on traffic that doesn’t convert
• Built-in telehealth infrastructure (EHR, video platform, credentialing)
• Both insurance and cash-pay patient flow

The math: Instead of gambling $5,000/month on marketing channels you may not have expertise in, you pay only when a qualified patient books with you. That’s guaranteed ROI vs. speculative investment.

For psychiatrists or PMHNPs exploring weight management as a revenue diversification strategy, joining an established platform removes the patient acquisition risk entirely while you build competence and volume.

Compliance Essentials: How to Practice Safely

Regardless of your state, follow these universal best practices:

1. Verify patient location every visitYou must be licensed in the state where the patient is physically located during the telehealth encounter. Document this.

2. Conduct appropriate evaluationsFor weight-loss prescribing, document:

• Height, weight, BMI
• Medical history (cardiovascular, endocrine, psychiatric)
• Current medications and potential interactions
• Contraindications (pregnancy, uncontrolled hypertension, etc.)
• Lifestyle factors and prior weight loss attempts
• Labs if clinically indicated (thyroid, glucose, lipids)

3. Use state PDMPsCheck your state’s prescription drug monitoring program before prescribing controlled substances. This is legally required in most states and critical for identifying drug-seeking behavior or dangerous polypharmacy.

4. Document informed consentPatients should understand:

• How the medication works and expected results
• Common and serious side effects
• Importance of diet and exercise
• Duration of treatment and follow-up plan
• Costs if not covered by insurance

5. Establish follow-up protocolsMost states and standard-of-care guidelines expect regular monitoring:

• Monthly early in treatment
• Quarterly minimum for ongoing therapy (required in Florida, recommended elsewhere)
• More frequent if side effects or complications arise

6. Coordinate careWeight loss intersects with primary care, endocrinology, cardiology. Send treatment summaries to patients’ PCPs (with patient consent) and refer when appropriate — managing GLP-1 side effects, handling diabetic patients, addressing cardiac concerns.

7. Stay current on regulationsThe DEA’s permanent telehealth rules are coming. State laws evolve. Subscribe to your state medical board updates and professional association newsletters.

FAQ: What Providers Actually Ask

Q: Can I prescribe Ozempic for weight loss via telehealth to new patients?

A: Yes, in almost every state where you’re licensed. Semaglutide is not a controlled substance, so it’s not subject to Ryan Haight Act restrictions. You must meet your state’s general telehealth standards — usually a live video evaluation that meets the standard of care. Document appropriate patient selection (BMI criteria) and informed consent.

Q: What about phentermine? Do I need an in-person visit?

A: It depends on your state and timing:

• Through Dec 2026: Federal DEA extension allows telehealth prescribing of controlled substances without in-person visits in most states
• New York: Requires in-person exam before controlled substance prescription (with narrow exceptions) — yes, you need an in-person visit or a referral from another provider who saw the patient
• Florida, Texas, California, Pennsylvania, Illinois: Currently allow telehealth prescribing of Schedule III-V controlled substances under federal allowance
• After 2026: Expect new DEA rules that may reimpose in-person requirements or mandate special telemedicine registrations

Q: As a PMHNP, can I open a weight-loss telehealth practice?

A: Legally risky without physician collaboration. Your scope of practice is psychiatric-mental health. State nursing boards expect you to practice within your training. Best approach: partner with a physician (family medicine or obesity specialist) who can provide oversight and handle medical complications. Alternatively, limit your practice to psychiatric patients where weight management is directly related to medication side effects or comorbid eating disorders.

Q: Do I need special certification to prescribe weight-loss medications?

A: No legal requirement, but it helps with credibility and risk management. The American Board of Obesity Medicine (ABOM) offers certification that demonstrates competence. Some malpractice insurers look favorably on additional training if you’re practicing outside your core specialty.

Q: What if my state doesn’t have specific weight-loss prescribing rules?

A: Follow the standard of care and FDA labeling. That means:

• Appropriate patient selection (BMI criteria)
• Ruling out secondary causes of obesity
• Incorporating lifestyle modification
• Monitoring for side effects and efficacy
• Following up regularlyEven without explicit state regulations, medical boards can discipline providers for substandard care.

Q: Can I treat patients in multiple states?

A: Only if you’re licensed in each state where patients are located during the visit. Multi-state telehealth requires multiple licenses unless you qualify for an interstate compact (Interstate Medical Licensure Compact for physicians, Nurse Licensure Compact for nurses).

Q: What’s the liability risk?

A: Same as any prescribing: if you meet the standard of care, document appropriately, and prescribe within your competence, your risk is manageable. The areas of concern:

• Prescribing without adequate evaluation (board complaint risk)
• Missing contraindications or drug interactions (malpractice risk)
• Practicing outside your scope as a specialist (board scrutiny)
• Violating state telehealth or prescribing laws (regulatory action)

Having appropriate malpractice insurance that covers telehealth and weight management is essential.

The Business Opportunity — And Why It Makes Sense for Psychiatric Providers

Why weight loss fits psychiatry:

1. Medication side effects: Antipsychotics cause significant weight gain. Psychiatrists managing these patients need tools to address metabolic complications. Prescribing metformin or GLP-1s for patients on olanzapine or clozapine is clinically appropriate and improves outcomes.

2. Comorbidity overlap: Depression, binge eating disorder, ADHD all intersect with obesity. Treating the whole patient means addressing weight.

3. Patient demand: Your existing patients may ask about weight-loss medications. Being able to manage this (or coordinate with a colleague) improves satisfaction and retention.

4. Revenue diversification: Psychiatric practices face reimbursement pressure. Weight management — especially cash-pay GLP-1 therapy — can generate additional revenue with strong margins.

The caution: Don’t launch a weight-loss clinic as a side hustle without the competence and infrastructure to do it right. But integrating evidence-based weight management into comprehensive psychiatric care? That’s defensible, patient-centered, and potentially profitable.

Next Steps: How to Start (or Scale) Safely

If you’re exploring weight-loss prescribing:

1. Verify your state’s rules using the state-specific guidance above
2. Get trained — take an obesity medicine CME course or pursue ABOM certification
3. Establish protocols for patient evaluation, informed consent, follow-up, and coordination with primary care
4. Choose your patient acquisition strategy — DIY marketing if you have the budget and patience, or join an established platform to remove acquisition risk
5. Ensure compliance infrastructure — PDMP registration, e-prescribing, HIPAA-compliant video platform, documentation templates
6. Consider malpractice coverage that explicitly includes telehealth and weight management

If you’re a PMHNP:

1. Assess scope honestly — can you justify this within psychiatric practice, or do you need physician collaboration?
2. Establish oversight — find a collaborating physician if required by your state or prudent for risk management
3. Focus on your niche — psychiatric patients with weight concerns, not general weight-loss services
4. Document competence — additional training, collaborative agreements, consultation arrangements

If you’re looking for qualified patient flow without marketing risk:

Platforms like Klarity Health handle patient acquisition, credentialing, and infrastructure. You control your schedule and only pay when you see patients — eliminating the $3,000-5,000/month marketing gamble. For providers testing the weight-loss market or scaling an existing practice, it’s the lowest-risk path to volume.

The Bottom Line

Psychiatrists and PMHNPs can legally prescribe weight-loss medications via telehealth in most states — but the specific rules vary dramatically by state and by medication type (GLP-1s vs. controlled substances).

Key takeaways:

• GLP-1 agonists (semaglutide, tirzepatide): Prescribable via telehealth in almost every state with appropriate evaluation and documentation. Not controlled substances, so no DEA in-person exam issue.

• Controlled substances (phentermine): Currently allowed via telehealth federally through 2026, but some states like New York require in-person exams. Check your state’s specific rules.

• Scope of practice: Psychiatrists (MDs) have broad authority but must practice competently. PMHNPs should collaborate with physicians unless treating psychiatric patients where weight is directly related to mental health care.

• State-specific compliance: Follow your state’s telehealth rules, PDMP requirements, obesity treatment standards (Florida, New Jersey, Virginia have explicit rules), and documentation expectations.

• Patient acquisition reality: DIY marketing costs $200-500+ per acquired patient when you count all expenses. Platform models offer pay-per-appointment economics with pre-qualified patients.

The regulatory landscape is in flux — DEA rules will change, state laws continue evolving, insurance coverage shifts. But for providers who stay informed, practice within their competence, and maintain rigorous compliance, telehealth weight-loss prescribing represents a legitimate clinical and business opportunity in 2025 and beyond.

Want to explore telehealth weight management without the patient acquisition risk? Klarity Health’s provider network offers pre-qualified patient flow, compliance infrastructure, and pay-per-appointment economics. Learn more about joining our provider network or explore the platform.

References and Citations

1. U.S. Department of Health & Human Services. (2026, January 2). HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026 [Press release]. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Florida Statutes § 456.47 – Use of Telehealth to Provide Services (Florida Telehealth Act). (2019, current through 2025). http://www.leg.state.fl.us/statutes/

3. Florida Administrative Code 64B8-9.012 – Standards for the Prescription of Drugs to Treat Obesity. (Effective August 8, 2022). https://regulations.justia.com/states/florida/64/64b8/chapter-64b8-9/section-64b8-9-012/

4. Goodwin Procter LLP. (2024, March 30). A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs [Client alert]. https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. McDermott Will & Emery. (2023, September 29). Weight-Loss Programs in Florida: State Law Considerations for GLP-1 Telehealth Providers. https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/

6. Medical Director Compliance Consulting. (2025). California Weight Loss Clinic & Telehealth Compliance Guide (2025). https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/

7. Medical Director Compliance Consulting. (2025). Texas Weight Loss Clinic & Telehealth Compliance Guide (2025). https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

8. New York Codes, Rules & Regulations Title 10, §80.63 – Prescribing of Controlled Substances (Amended May 2025). https://www.law.cornell.edu/regulations/new-york/10-NYCRR-80.63

9. Landi, H. (2025, February 13). Primary care doctors concerned about telehealth GLP-1 boom: survey. Fierce Healthcare. https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey

10. California Medical Association. (2025, December 2). GLP-1 medications for weight loss will no longer be covered by Medi-Cal. https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal

11. Center for Connected Health Policy. (2025, November 21). State Telehealth Policies for Online Prescribing. https://www.cchpca.org/topic/online-prescribing/

12. Pennsylvania Department of Health. (2022). Prescription Drug Monitoring Program FAQs. https://www.pa.gov/agencies/health/programs/opioids/prescribers-and-providers/prescribing-guidelines.html

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated